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Sexual dimorphism is observed in most human diseases. The difference in the physiology and genetics between
sexes can contribute tremendously to the disease prevalence, severity, and outcome. Both hormonal and genetic
differences between males and females can lead to differences in gene expression patterns that can influence
disease risk and course. MicroRNAs have emerged as potential regulatory molecules in all organisms. They can have
a broad effect on every aspect of physiology, including embryogenesis, metabolism, and growth and development.
Numerous microRNAs have been identified and elucidated to play a key role in cardiovascular diseases, as well as in
neurological and autoimmune disorders. This is especially important as microRNA-based tools can be exploited as
beneficial therapies for disease treatment and prevention. Sex steroid hormones as well as X-linked genes can have
a considerable influence on the regulation of microRNAs. However, there are very few studies highlighting the role
of microRNAs in sex biased diseases. This review attempts to summarize differentially regulated microRNAs in males
versus females in different diseases and calls for more attention in this underexplored area that should set the basis
for more effective therapeutic strategies for sexually dimorphic diseases.Introduction
Many complex regulatory steps are important in the
conversion and dissemination of genetic information to
molecular effectors. This regulation is fine tuned by a
number of transcriptional and post transcriptional mecha-
nisms. Sex differences can have major contributions in de-
fining the course of these regulatory steps. Whether it is
the presence of a Y chromosome, an extra X chromosome
or a difference in the hormonal milieu, these gender dif-
ferences are remarkably reflected in the disease outcomes.
Gender differences have been already highlighted in a
number of diseases and disorders associated with neuro-
development, cancers, cardiovascular and immune sys-
tems [1-10]. MicroRNAs regulate various physiological
processes ranging from cell growth and differentiation to
cell metabolism, development, morphogenesis, maturation
and apoptosis [11-21]. The dysregulation of microRNAs
and consequently of their target genes has been widely* Correspondence: meghbali@ucla.edu
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article, unless otherwise stated.linked to various pathologic conditions of the heart, lung
and brain, as well as in many cancers [22-33]. Thus, it is
worthwhile to examine their role in the context of sex dif-
ferences and disease outcome.
There is a differential expression of microRNAs in
males and females. This sex-biased expression of micro-
RNAs has been observed both in invertebrates as well as
in higher organisms [34-38]. The sex difference in the
expression of microRNAs has also been observed in em-
bryonic stem cell differentiation. In particular, it has
been shown that miR-302 is enriched in the male embry-
onic stem cell differentiation and germ line determin-
ation, but not in female cells [39]. Another example is
the sex-associated differential expression of microRNAs
during lung development, which ultimately leads to dif-
ferences in the structure and function of lungs between
males and females [40]. This sex-biased difference in
microRNA expression is of great biomedical interest.
The contribution of differential microRNA expression in
sexually dimorphic disease development has also been
explored to some extent [41,42]. This review will high-
light our current knowledge on the differential expression
of microRNAs between genders, the sex chromosome and
sex hormone-mediated regulation of microRNAs and howCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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the sex differences in the disease outcome.
Review
MicroRNA biogenesis
MicroRNAs are small, non-coding, approximately 19-
22-nucleotide-long RNA molecules. Their function is to
regulate gene expression by mRNA degradation or to at-
tenuate translation of their target genes. The very first
identified microRNAs, lin-4 and let-7 were discovered in
Caenorhabditis elegans in the early 1990s [43-45]. Micro-
RNAs are reported in a wide variety of organisms ran-
ging from single-cell organisms to metazoans, plants and
mammals [46-49]. In mammals, it is estimated that ap-
proximately 60% of all protein-coding genes are under
microRNA regulation [50,51]. MicroRNAs are involved in
the regulation of virtually all cellular processes including
metabolism, development, morphogenesis, programmed
cell death, angiogenesis and so on [14,21,33,52-57]. Their
dysregulated expression is also associated with human
pathologies, including neurological disorders, cardiovascu-
lar diseases and cancer [27,28,30].
With the help of RNA polymerase II, microRNAs are
transcribed from long precursor molecules called pri-
miRNA present as independent genes or in the introns of
protein coding genes. Two RNA polymerase III enzymes,
Drosha and Dicer, act on these hairpin pri-miRNAs. Drosha
cleaves the hairpin into approximately 70 nucleotide pre-
miRNA molecule, which then is exported out of the nu-
cleus by active transport. In the cytosol, Dicer processes it
to an approximately 20-bp miRNA/miRNA* duplex. One
strand of this duplex represents the mature microRNA.
This mature miRNA is then incorporated in a multi pro-
tein complex, the miRNA-induced silencing complex
(miRISC). MicroRNA-induced translational repression is
guided within miRISC. Lastly, the assembly and function
of ribonucleases and miRISCs are assisted by proteins and
key cofactors including argonaute proteins [43-45,58]. The
regulation of microRNA biogenesis is important for the
tissue- and development-specific control of microRNA
expression. The sophisticated control of microRNA bio-
genesis, function and decay is essential, as these regulatory
molecules play a fundamental role in all known cellular
processes.
Sex-specific difference in microRNA expression
Hormonal and genetic differences between males and fe-
males bear considerable impact on health and disease.
One particular area of interest is the microRNAs which
can have broad effect on downstream signaling path-
ways. Differences in miRNA expression between males
and females can help us further understand the bio-
logical and physiological differences between the sexes.
These sex differences in microRNA expression are aresult of both hormonal and genetic differences between
the sexes.
Sex hormonal regulation of microRNAs
Several sex steroid hormones, such as estradiol, proges-
terone and testosterone, regulate microRNA expression
[58-64]. A distinct sex-specific pattern of microRNA ex-
pression in neonatal rodent brains was observed. This
difference in expression almost disappeared when the
conversion of testosterone to estradiol was blocked in
males, suggesting that microRNAs are regulated by es-
trogens [65]. Sex hormones bind to nuclear hormone re-
ceptors to directly or indirectly alter gene expression.
This ligand-bound nuclear hormone complex binds to
the promoter elements of multiple genes, recruits coacti-
vators or corepressors, and regulates gene transcription.
MicroRNAs are either embedded in their host genes or
have their own promoter elements. They are either core-
gulated or regulated in the same manner as their host
genes. In addition, nuclear hormone receptors can regu-
late multiple downstream target genes. These target genes
could induce or repress microRNAs as a part of a bigger
molecular network [66-68]. Thus, the hormonal regula-
tion of microRNAs could be direct as well as indirect. An-
other important mechanism of hormonal regulation of
microRNAs is at the level of the microRNA processing
machinery. There are multiple steps involved in the pro-
cessing of microRNAs. The ribonucleases Drosha and
Dicer are part of larger protein complexes, and play key
roles in the activation or repression of these complexes to
regulate microRNA maturation. Furthermore, hormones
can also regulate Drosha and Dicer, thus broadly regulat-
ing microRNAs. For example, estradiol signaling has been
shown to alter the expression of argonaute, Drosha and
Dicer [69-73]. Thus, hormonal regulation of microRNAs
can occur both directly by binding to the promoter ele-
ments of microRNAs or indirectly via regulation of post
transcriptional processing proteins. This could have broad
signaling effects at the molecular and cellular level.
Sex chromosomal regulation of microRNAs
Differences in the expression of microRNAs can be partly
attributed to a differential regulation by sex chromosome
genes. Gene expression in males and females differs since
females possess two copies of the X chromosome and lack
the Y chromosome. Since males are hemizygous for the X
chromosome-linked genes, they are more prone to dis-
eases associated with recessive mutations. There is a high
density of microRNAs on the X chromosome. According
to miRBase microRNA archive (www.miRBase.org 2013),
the X chromosome encodes 113 microRNAs whereas Y
chromosome encodes only 2. Many genes in the X
chromosome are inactivated in order to balance the ex-
pression of most but not all X-linked genes in females and
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active X chromosome in humans escape inactivation
[74-77], which in some cases results in higher expression
of the X gene in females than in males. The inactivation
status of X-linked miRNAs is not well characterized. Inter-
estingly, the expression of sex-biased microRNAs in the
neonatal brain could stem from both hormone and sex
chromosome effects [78].
Sex-biased differences in microRNA expression influences
disease pathogenesis
Males and females differ in disease outcome and patho-
genesis. In a number of autoimmune diseases, females
have higher incidence of disease than males [10,42,79,80].
In contrast, the pathogenesis of many cancers is higher in
males than females [81]. The incidence of cardiovascular
diseases is also higher in men than women before meno-
pause [82,83]. Therefore, differential expression of micro-
RNAs between the sexes may be an important underlying
mechanism for gender-biased disease outcome (Table 1).
Autoimmune diseases
Autoimmunity results from the misdirected response of
immune system to body’s healthy cells, leading to auto-
immune diseases including rheumatoid arthritis, type I
diabetes and systemic lupus erythematosus [89,90]. Mul-
tiple factors, hormonal or genetic, either protect males
or increase vulnerability of females [10]. Behavioral dif-
ferences between the sexes could also alter susceptibility
to infection [91]. The X chromosome is enriched in
microRNAs and there is a possibility that microRNAs
may escape X-linked inactivation [78,92]. This could re-
sult in the suppression of many microRNA-regulated
target genes involved in immunosuppressive pathways,
leading to a heightened autoimmune response in femalesTable 1 MicroRNAs showing sex-biased expression in differen
Disease/development MicroRNAs
Autoimmune diseases
Systemic lupus erythematosus miR-182 cluster, miR-31, and miR-148a [84]
Neurodegenerative diseases
Schizophrenia miR-30b [85]
let-7f-2, miR-18b, miR-505, miR-502, miR-188
miR-325, miR-660 and miR-509-3 [41]
Cerebral ischemia miR-23a [37]
Neurodevelopment miR-322, miR-574, and miR-873 [65]
Metabolic diseases miR-221, let-7 g [86]
Breast cancer miR17, let-7a [87];
miR-137 [35]
Liver fibrosis miR-29a, miR-29b [88]and their predisposition to autoimmune diseases [93,94].
Predisposition of women to systemic lupus erythemato-
sus is due to overexpression of immune active genes,
resulting in T cell autoreactivity. Various factors contrib-
ute to the pathogenesis of systemic lupus erythematosus.
These include genetic factors such as skewed X chromo-
some inactivation, environmental and epigenetic factors
such as DNA methylation and smoking, and hormones
or microRNAs that could possibly make women more
susceptible [95-97]. Interestingly, in the NZB/WF1 mur-
ine model that closely mimics human lupus, a clear sex
difference in the systemic lupus erythematosus-associated
microRNAs was observed. Particularly, increased expres-
sion of miR-182 cluster, miR-155, miR-31, and miR-148a
was observed in female NZB/WF1 mice at an age after
the onset of lupus. Administration of estrogens to cas-
trated male NZB/WF1 mice resulted in the expression
of female-associated systemic lupus erythematosus micro-
RNAs including the miR-182 cluster, miR-379, and miR-
148a, thus demonstrating the role of sex hormones in
the regulation of sexual dimorphism of microRNAs [84].
In addition, estrogens are important modulators of the
immune system and contribute to the gender difference in
autoimmune disease susceptibility [98-100]. Estrogen treat-
ment augments innate immune response of murine splenic
lymphocytes to Lipopolysaccharide by manipulating
select microRNAs, including miR146a and miR-223 [101].
Thus, estrogen-mediated regulation of microRNAs may
serve as an important parameter in gender-biased disease
susceptibility.
Neurodegenerative disorders
The precise temporal regulation of microRNAs is espe-
cially important in the development of the central ner-







M< F Estrogens -
M > F Estrogens
, No expression changes reported
(only mutational changes
between disease and control)
X chromosome
M < F - -
M < F Estrogens -
M < F - -
M < F - -
M < F promoter methylation of miR-137 - -
M < F Estrogens -
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the microRNA processing enzyme Dicer in zebrafish re-
sulted in the disruption of neuronal differentiation [21].
MicroRNAs are involved in various neurologic processes
including neuronal development (miR-430, miR-9, miR-10)
[21,102-106] and neuronal cell maintenance (miR-29a/b,
miR-134) [107,108]. Also, of scientific interest, is the role
of microRNAs in the aging brain since there is a global
downregulation of gene expression in the brain with age
[109-112]. It is also well known that the functional and
cognitive decline in the aging brain differs between men
and women, as many neurological disorders such as
Alzheimer’s disease are expressed differentially between
the sexes. Sex hormones and chromosomes could very
well contribute to this difference [113-115]. MicroRNAs
including miR-125a/b, miR-495 and miR-181 have been
shown to be dysregulated in a variety of neurological dis-
orders such as Alzheimer’s disease. These microRNAs also
target proteins such as β-site amyloid precursor protein-
cleaving enzyme-1 that are critical in the pathology of
Alzheimer’s disease [116-118]. Hormonal regulation of
microRNAs is attributed to neurodegenerative disorders
[65]. It is also speculated that sex chromosomes could
regulate microRNAs in neurodegenerative disorders [78].
The effects of ionizing radiation on the expression of
microRNAs were studied in different brain regions in
male and female mice. Interestingly, the number of micro-
RNAs that showed changes in expression upon exposure
to radiation was larger in females than males. Notably, the
expression of miR-29a was downregulated only in the
frontal cortex region of females accompanied by an in-
crease in the protein levels of miR29a target DNMT3a, a
DNA methyltransferase. It is possible that an increase in
DNA methylation via miR29a downregulation serves as a
protective mechanism in females against the adverse ef-
fects of radiation [34]. In contrast, only a few studies in
humans have measured sex differences in microRNA ex-
pression in the brains of patients with neurological dis-
eases such as Alzheimer’s disease or schizophrenia. The
levels of miR-30b were observed to be significantly down-
regulated in the brains of female schizophrenic patients
compared to males. MiR-30b was shown to be regulated
by estrogens and therefore, it is most likely under
hormonal control [85]. Another relevant study specifically
focused on the association of microRNAs on the X chromo-
some with high prevalence of schizophrenia in males com-
pared to females. Mutations in X-linked microRNAs that
can possibly predispose males to schizophrenia were iden-
tified. Some key targets identified for these microRNAs
include Neuregulin-1, Disrupted in schizophrenia-1, and
Regulator of G-protein signaling-4, which have been pre-
viously described as candidate genes for schizophrenia
[41]. The underlying cause of cerebral ischemia differs be-
tween males and females. In males the cause of stroke-related death is primarily due to caspase-independent
mechanisms, whereas in females it involves caspase-
dependent pathways [119-121]. X-linked inhibitor of
apoptosis, which is the primary endogenous inhibitor
of caspases, is significantly reduced in post-stroke females
compared to no significant changes in males. This was at-
tributed to the differential expression of the microRNA
miR-23a in the male and female brains. Also, the X-linked
inhibitor of apoptosis was characterized as the bona fide
target of miR-23a, thus implicating miR23a as a candidate
for sexually dimorphic diseases [37]. Many neurodevelop-
mental disorders including schizophrenia and autism are
linked to prenatal stress [122,123]. In a murine model,
early gestation was reported to be the period where male
mouse embryos are most susceptible to maternal stress.
As adults, these male mice showed cognitive defects
typical of human neurodegenerative disease. They also
showed dysmasculization in their response to stress,
as well as a female pattern of gene expression associated
with neurodevelopment. The microRNA profile in these
male brains included significant downregulation of miR-
322, miR-574, and miR-873, showing similarity to control
female brains [65]. These data further confirm the import-
ant role of microRNAs in the development of the sexually
dimorphic brain.
Metabolism
Metabolic syndrome includes all the risk factors that can
increase the susceptibility to, or lead to health disorders,
including heart disease, type 2 diabetes, and stroke. Be-
cause of high obesity rate, metabolic syndrome is fast ap-
proaching as one of the major risk factors for heart disease
[124-126]. Sex is a significant modifier for metabolic
syndrome-related cardiovascular and non-cardiovascular
complications. Wang et. al. discovered that miR-221 and
let- 7 g were expressed more prominently in the plasma of
women than men manifesting metabolic syndrome [86].
This may have significant implications in the susceptibility
of these women to cardiovascular risk factors. Interest-
ingly, the expression of these microRNAs positively corre-
lated with the increase in number of risk components
associated with metabolic syndrome including high blood
pressure and low HDL levels.
Cardiovascular diseases
The incidence and progression of heart disease is mark-
edly higher in men than in age-matched women before
menopause, whereas after menopause the incidence is simi-
lar or even higher in women than age-matched men [82,83].
The lower incidence and better protection of women
against coronary artery disease during reproductive years
is attributed to the presence of female sex hormones
[127]. The protective role of estradiol has been highlighted
in the context of myocardial ischemia/reperfusion injury
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addition, the regulation of microRNAs by estrogens and
other sex hormones is well established [58-64]. However,
the link between sex differences in microRNAs and their
effect on the incidence and course of cardiovascular dis-
ease is largely unexplored. Future studies on this issue will
help in the understanding of sex-biased difference in car-
diovascular disease.
Cancer and liver disease
The dysregulation of microRNAs is implicated in the
pathogenesis of many cancers. For instance, the regula-
tion of microRNAs is involved in the progression of
breast cancer. Breast cancer is prevalent among women
in the western world, with much lower incidence among
males [129-131]. Multiple microRNAs have dysregulated
expression in breast cancer versus normal controls both
in breast tissue and in blood circulation [132-135]. Of
interest, Pinto et. al. presented a significant correlation
between miR17 and let-7a frequency and regulation in
familial breast cancer in women compared to men [87].
Langevin et. al. also show that promoter methylation of
miR-137 occurs frequently in squamous cell carcinoma of
the head and neck. This microRNA is implicated in cell
cycle control and differentiation. This aberrant methyla-
tion shows a bias toward females and may be associated
with environmental and personal risk factors [35].
Some chronic liver diseases manifest different progres-
sion rates in males versus females. For example, liver fi-
brosis is one of the hallmarks of chronic viral hepatitis
and has a higher incidence in males than females. It is
characterized by extensive deposition of collagens in the
extracellular matrix [136,137]. In the carbon tetrachlor-
ide mouse model of fibrosis, females are more protected
against liver fibrosis than males. This has been attributed
to the induction of miR-29a and miR-29b by estrogens
in females. MiR-29 family members decrease the content
of collagens by directly targeting them and thus block
the process of development of fibrosis [88,138].
Conclusions
In recent years, microRNAs have emerged as powerful
regulatory molecules. Gain and loss of function studies
in various animal models mimicking human disease have
shed light on the functional role and target specification
of microRNAs. However, the role of miRNAs in mediat-
ing sex biases in diseases is understudied and under-
appreciated. There is a plethora of literature showing
sexual dimorphism in the context of neurological and
autoimmunity disorders. This is attributed to both hor-
monal and sex chromosome differences between males
and females. Estrogens have been shown to regulate a
number of microRNAs in various cell studies. Similarly,
the X chromosome is enriched in a number of microRNAsinvolved in various physiological processes, especially
immunity. Thus, it is likely that these microRNAs can
influence sex-specific responses to disease prevalence,
pathogenesis, and outcome. Further research in exploring
the gender-specific roles of microRNAs is extremely im-
portant for the development of effective therapeutic strat-
egies for sexually dimorphic diseases.
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